India's Panacea Biotec rises to record high on EU-backed dengue vaccine project
BUZZ-India's Panacea Biotec rises to record high on EU-backed dengue vaccine project ** Shares of Panacea Biotec PNCA.NS jump as much as 12% to an all-time high of 620 rupees
** Stock set for a sixth consecutive session of gains, if current trend holds
** Trades 7.3% higher at 593.45, as of 10:09 a.m. IST
** The vaccine and drugmaker launches four-year Denstar project to support licensure of its dengue vaccine DengiAll in sub-Saharan Africa
** Project funded by EU-backed European & Developing Countries Clinical Trials Partnership (EDCTP3) programme, with a consortium of 10 partners across nine countries
** Vaccine targets all four dengue sterotypes and is in late-stage development in India
** More than 2.6 million shares traded, more than 4 times their 30 day avg
** YTD, PNCA stock up ~57%
(Reporting by Urvi Dugar in Bengaluru)
Recent news on Panacea Biotec
See all newsBrief: Panacea Biotec Receives Letter Of Award For BOPV Supply Worth $8.205 Million
Brief: Panacea Biotec Unit Gets Show Cause Notice Alleging Total Tax Liability Of 40.6 Million Rupees
Brief: Panacea Biotec Files Appeal Against Fourth Industrial Tribunal (Mohali) Award
India's Panacea Biotec rises to record high on EU-backed dengue vaccine project
India Stocks: Indian shares rise as banks gain on RBI forex swap facility